Coherus BioSciences (NASDAQ:CHRS) is set to give its latest quarterly earnings report on Monday, 2026-03-09. Here's what investors need to know before the announcement.

Analysts estimate that Coherus BioSciences will report an earnings per share (EPS) of $-0.34.

Investors in Coherus BioSciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Earnings History Snapshot

In the previous earnings release, the company missed EPS by $0.01, leading to a 10.07% drop in the share price the following trading session.

Here's a look at Coherus BioSciences's past performance and the resulting price change:

Tracking Coherus BioSciences's Stock Performance

Shares of Coherus BioSciences were trading at $1.76 as of March 05. Over the last 52-week period, shares are up 68.75%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

Discovering Coherus BioSciences: A Closer Look

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Key Indicators: Coherus BioSciences's Financial Health

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Coherus BioSciences displayed positive results in 3 months. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 91.19%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -307.07%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -34.23%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -7.43%, the company showcases effective utilization of assets.

Debt Management: Coherus BioSciences's debt-to-equity ratio stands notably higher than the industry average, reaching 0.46. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

To track all earnings releases for Coherus BioSciences visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.